{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:14:47Z","timestamp":1784589287234,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40264-022-01166-3","type":"journal-article","created":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T13:02:43Z","timestamp":1646485363000},"page":"287-295","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Drug\u2013Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7030-0442","authenticated-orcid":false,"given":"Wajd","family":"Alkabbani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1136-964X","authenticated-orcid":false,"given":"Ryan","family":"Pelletier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8722-460X","authenticated-orcid":false,"given":"Michael A.","family":"Beazely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Labib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breanna","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6891-8721","authenticated-orcid":false,"given":"John-Michael","family":"Gamble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,5]]},"reference":[{"issue":"10","key":"1166_CR1","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1007\/s00125-018-4663-6","volume":"61","author":"BC Lupsa","year":"2018","unstructured":"Lupsa BC, Inzucchi SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia. 2018;61(10):2118\u201325.","journal-title":"Diabetologia"},{"issue":"1","key":"1166_CR2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12933-020-01071-y","volume":"19","author":"L Ni","year":"2020","unstructured":"Ni L, Yuan C, Chen G, et al. SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol. 2020;19(1):98.","journal-title":"Cardiovasc Diabetol"},{"issue":"22","key":"1166_CR3","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B,\u00a0Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"1166_CR4","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"1166_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"15","key":"1166_CR6","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425\u201335.","journal-title":"N Engl J Med"},{"issue":"2","key":"1166_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL,\u00a0Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129\u201339.","journal-title":"N Engl J Med"},{"issue":"15","key":"1166_CR8","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"21","key":"1166_CR9","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"2","key":"1166_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117\u201328.","journal-title":"N Engl J Med"},{"issue":"19","key":"1166_CR11","doi-asserted-by":"publisher","first-page":"e009835","DOI":"10.1161\/JAHA.118.009835","volume":"7","author":"H Qu","year":"2018","unstructured":"Qu H,\u00a0Guo M, Chai H, et al. Effects of coenzyme Q10 on statin-induced myopathy: an updated meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7(19):e009835.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"1166_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/bcp.12687","volume":"80","author":"RB Iwere","year":"2015","unstructured":"Iwere RB, Hewitt J. Myopathy in older people receiving statin therapy: a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;80(3):363\u201371.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"1166_CR13","doi-asserted-by":"publisher","first-page":"e017587","DOI":"10.1136\/bmjopen-2017-017587","volume":"7","author":"Z Zhou","year":"2017","unstructured":"Zhou Z, Albarqouni L, Breslin M, et al. Statin-associated muscle symptoms (SAMS) in primary prevention for cardiovascular disease in older adults: a protocol for a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2017;7(9):e017587.","journal-title":"BMJ Open"},{"key":"1166_CR14","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.amjcard.2006.08.063","volume":"99","author":"SJ Kamal-Bahl","year":"2007","unstructured":"Kamal-Bahl SJ, Burke T, Watson D, et al. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol. 2007;99:530\u20134.","journal-title":"Am J Cardiol"},{"issue":"7","key":"1166_CR15","doi-asserted-by":"publisher","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","volume":"158","author":"H Zhang","year":"2013","unstructured":"Zhang H,\u00a0Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158(7):526\u201334.","journal-title":"Ann Intern Med"},{"key":"1166_CR16","unstructured":"Knauer MJ. The role of drug transporters in statin-induced myopathy.In: Electronic Thesis and Dissertation Repository; 2012."},{"issue":"5","key":"1166_CR17","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/archinte.163.5.553","volume":"163","author":"CM Ballantyne","year":"2003","unstructured":"Ballantyne CM,\u00a0Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003;163(5):553\u201364.","journal-title":"Arch Intern Med"},{"issue":"12","key":"1166_CR18","doi-asserted-by":"publisher","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","volume":"150","author":"TR Joy","year":"2009","unstructured":"Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009;150(12):858\u201368.","journal-title":"Ann Intern Med"},{"issue":"5","key":"1166_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9734\/BJMMR\/2017\/33253","volume":"21","author":"U Kabadi","year":"2017","unstructured":"Kabadi U. Marked weight loss, muscle wasting and fatigue on administration of empagliflozin in a subject with type 2 diabetes. Br J Med Med Res. 2017;21(5):1\u20137.","journal-title":"Br J Med Med Res."},{"key":"1166_CR20","first-page":"20","volume":"2020","author":"F Gao","year":"2020","unstructured":"Gao F, Hall S, Bach LA. Myopathy secondary to empagliflozin therapy in type 2 diabetes. Endocrinol Diabetes Metab Case Rep. 2020;2020:20\u20130017.","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"7","key":"1166_CR21","doi-asserted-by":"publisher","first-page":"585","DOI":"10.7326\/L20-0549","volume":"173","author":"E Brailovksi","year":"2020","unstructured":"Brailovksi E, Kim RB, Juurlink D. Rosuvastatin myotoxicity after starting canagliflozin treatment: a case report. Ann Intern Med. 2020;173(7):585\u20137.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1166_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00592-019-01378-7","volume":"57","author":"IC Antonazzo","year":"2020","unstructured":"Antonazzo IC, Poluzzi E, Forcesi E, et al. Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug-drug interactions through the FDA adverse event reporting system. Acta Diabetol. 2020;57(1):71\u201380.","journal-title":"Acta Diabetol"},{"issue":"6","key":"1166_CR23","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/17425255.2021.1921735","volume":"17","author":"PN Lalagkas","year":"2021","unstructured":"Lalagkas PN,\u00a0Poulentzas G, Kontogiorgis C, et al. Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence. Expert Opin Drug Metab Toxicol. 2021;17(6):697\u2013705.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"1166_CR24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s12325-011-0098-x","volume":"29","author":"S Kasichayanula","year":"2012","unstructured":"Kasichayanula S,\u00a0Chang M, Liu X, et al. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Adv Ther. 2012;29(2):163\u201377.","journal-title":"Adv Ther"},{"issue":"3","key":"1166_CR25","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/cpdd.166","volume":"4","author":"D Devineni","year":"2015","unstructured":"Devineni D, Manitpisitkul P, Murphy J, et al. Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants. Clin Pharmacol Drug Dev. 2015;4(3):226\u201336.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"11","key":"1166_CR26","doi-asserted-by":"publisher","first-page":"973","DOI":"10.5414\/CP202117","volume":"52","author":"S Macha","year":"2014","unstructured":"Macha S,\u00a0Lang B, Pinnetti S, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and simvastatin following co-administration in healthy volunteers. Int J Clin Pharmacol Ther. 2014;52(11):973\u201380.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"1166_CR27","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/cpdd.472","volume":"8","author":"VK Dawra","year":"2019","unstructured":"Dawra VK,\u00a0Cutler DL, Zhou S, et al. Assessment of the drug inter-action potential of ertugliflozin with sitagliptin, metformin, glimepiride, or simvastatin in healthy subjects. Clin Pharmacol Drug Dev. 2019;8(3):314\u201325.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"23","key":"1166_CR28","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMsa2032271","volume":"384","author":"M Fang","year":"2021","unstructured":"Fang M, Wang D, Coresh J, et al. Trends in diabetes treatment and control in US adults, 1999\u20132018. N Engl J Med. 2021;384(23):2219\u201328.","journal-title":"N Engl J Med"},{"key":"1166_CR29","unstructured":"US Food and Drug Administration. FDA AEs reporting system (FAERS) public dashboard. 2017. https:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/ucm070093.htm. Accessed 9 Jun 2021."},{"issue":"5","key":"1166_CR30","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1002\/cpt.2172","volume":"109","author":"A Lavertu","year":"2021","unstructured":"Lavertu A, Vora B, Giacomini KM, et al. A new era in pharmacovigilance: toward real-world data and digital monitoring. Clin Pharmacol Ther. 2021;109(5):1197\u2013202.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1166_CR31","doi-asserted-by":"publisher","first-page":"10709","DOI":"10.1038\/s41598-021-90108-7","volume":"11","author":"B Wu","year":"2021","unstructured":"Wu B, Hu Q, Tian F, et al. A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data. Sci Rep. 2021;11(1):10709.","journal-title":"Sci Rep"},{"key":"1166_CR32","doi-asserted-by":"crossref","unstructured":"Poluzzi E, Raschi E, Piccinni C, et al. Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS). 2012. In: Karahoca A , editor. Data mining applications in engineering and medicine. Croatia: InTech; 2012: p. 265\u2013302.","DOI":"10.5772\/50095"},{"issue":"5","key":"1166_CR33","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00228-014-1658-1","volume":"70","author":"B Grundmark","year":"2014","unstructured":"Grundmark B, Holmberg L, Garmo H, et al. Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area. Eur J Clin Pharmacol. 2014;70(5):627\u201335.","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"1166_CR34","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.numecd.2017.10.008","volume":"27","author":"E Raschi","year":"2017","unstructured":"Raschi E, Parisotto M, Forcesi E, et al. Adverse events with sodium-glucose co-transporter-2 inhibitors: a global analysis of international spontaneous reporting systems. Nutr Metab Cardiovasc Dis. 2017;27(12):1098\u2013107.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"7","key":"1166_CR35","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40264-014-0187-2","volume":"37","author":"H G\u00e9niaux","year":"2014","unstructured":"G\u00e9niaux H,\u00a0Assaf D, Miremont-Salam\u00e9 G, et al. Performance of the standardised MedDRA\u00ae queries for case retrieval in the French spontaneous reporting database. Drug Saf. 2014;37(7):537\u201342.","journal-title":"Drug Saf"},{"issue":"6","key":"1166_CR36","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40264-016-0405-1","volume":"39","author":"AF Wisniewski","year":"2016","unstructured":"Wisniewski AF,\u00a0Bate A, Bousquet C, et al. Good signal detection practices: evidence from IMI PROTECT. Drug Saf. 2016;39(6):469\u201390.","journal-title":"Drug Saf"},{"issue":"6","key":"1166_CR37","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"JL Montastruc","year":"2011","unstructured":"Montastruc JL,\u00a0Sommet A, Bagheri H, et al. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72(6):905\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"1166_CR38","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13(8):519\u201323.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9\u201310","key":"1166_CR39","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s002280000215","volume":"56","author":"EP Van Puijenbroek","year":"2000","unstructured":"Van Puijenbroek EP,\u00a0Egberts AC, Heerdink ER, et al. Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol. 2000;56(9\u201310):733\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"1166_CR40","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1365-2125.2007.02900.x","volume":"64","author":"BT Thakrar","year":"2007","unstructured":"Thakrar BT, Grundschober SB, Doessegger L. Detecting signals of drug-drug interactions in a spontaneous reports database. Br J Clin Pharmacol. 2007;64(4):489\u201395.","journal-title":"Br J Clin Pharmacol"},{"key":"1166_CR41","doi-asserted-by":"crossref","unstructured":"Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 46(D1):D1074\u201382.","DOI":"10.1093\/nar\/gkx1037"},{"key":"1166_CR42","doi-asserted-by":"publisher","first-page":"S369","DOI":"10.1016\/j.jval.2018.09.2200","volume":"21","author":"E Beulah","year":"2018","unstructured":"Beulah E, Reddy N, Subeesh V, et al. Weber effect: an extended analysis for ten years of reporting trends in FDA Adverse Event Reporting System (FAERS). Value Health. 2018;21:S369.","journal-title":"Value Health."},{"issue":"2","key":"1166_CR43","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","volume":"74","author":"JL Faillie","year":"2019","unstructured":"Faillie JL. Case-non-case studies: principle, methods, bias and interpretation. Therapie. 2019;74(2):225\u201332.","journal-title":"Therapie"},{"issue":"5","key":"1166_CR44","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/bcp.13186","volume":"83","author":"RNVS Mamidi","year":"2017","unstructured":"Mamidi RNVS,\u00a0Dallas S, Sensenhauser C, et al. In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. Br J Clin Pharmacol. 2017;83(5):1082\u201396.","journal-title":"Br J Clin Pharmacol"},{"key":"1166_CR45","doi-asserted-by":"crossref","unstructured":"Teng C, Frei CR. Delirium associations with antibiotics: a pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS). Drugs Real World Outcomes. 2021. Epub ahead of print.","DOI":"10.1007\/s40801-021-00268-1"},{"issue":"1","key":"1166_CR46","first-page":"113","volume":"55","author":"B B\u00e9gaud","year":"2000","unstructured":"B\u00e9gaud B, Dangoumau J. Pharmacoepidemiology: definitions, problems, methodology. Therapie. 2000;55(1):113\u20137.","journal-title":"Therapie"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01166-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-022-01166-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01166-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T10:29:09Z","timestamp":1681554549000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-022-01166-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1166"],"URL":"https:\/\/doi.org\/10.1007\/s40264-022-01166-3","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"17 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No direct funding was received for this project.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Wajd Alkabbani, Ryan Pelletier, Michael A Beazely, Youssef Labib, Breanna Quan, and John-Michael Gamble declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"No additional data available.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Available upon request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"WA wrote the first draft of the manuscript and conducted the statistical analysis. WA, RP, and JMG were involved in the conception of the study. All authors were involved in the study design, interpretation of results, and critical review of the manuscript. All authors read and approved the final version. JMG affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors Contributions"}}]}}